BioSig Technologies Announces PURE-EP System Clinical Data
PURE EP System is designed to improve signal fidelity and uncover the full range of ECG and intra-cardiac signals during complex ablation procedures.
June 22, 2021
CLINICAL TRIALS, STUDIES, REGISTRIES, DATA
View the latest clinical trials, studies, data, and updates.
DEFINE GPS Global Multicenter Study – First Patient Enrolled: Study to assess Superiority of PCI Procedures Guided by Co-registered iFR and Interventional Angiography
The global, multi-center, prospective, randomized controlled DEFINE GPS study will investigate if guidance by instantaneous wave-free ratio (iFR) measurements co-registered on the angiogram demonstrates superior outcomes and improves the cost-effectiveness of percutaneous coronary intervention (PCI) procedures to open blocked coronary arteries.
June 22, 2021
QuickSee Handheld Autorefractor Can Dramatically Increase Access to Eyeglasses According to a Study
The device is designed to reduce global uncorrected refractive error.
June 21, 2021
Surfacide Peer-Reviewed Study: Confirms UV-C Extremely Effective in Killing SARS-CoV-2 On Surfaces and Air in Environments
The study was led by Dr. Randy Loftus, MD, an Associate Professor of Anesthesiology and Critical Care Medicine at University of Iowa Hospital and Clinics, and Dr. Franklin Dexter, MD, PhD, University of Iowa Professor in the Department of Anesthesia.
June 17, 2021
CarThera Reports Preclinical Results in the Testing of the Combination of SonoCloud® Technology with Immunotherapies
The goal of the preclinical work was to investigate the following: to see if low-intensity pulsed ultrasound could enhance the therapeutic efficacy of anti-PD-1 in C57BL/6 mice – bearing intracranial GL261 gliomas; epidermal growth factor receptor variant III (EGFRvIII) specific chimeric antigen receptor (CAR) T cells within NSG mice with established EGFRvIII-U87 gliomas (epidermal growth factor receptor variant III); and a genetically-engineered antigen-presenting cells (APC)-based therapy, producing the T-cell attracting chemokine CXCL10 in the GL261-bearing mice
June 9, 2021
Guard Medical Reports Enrollment of the first 5 Patients in the Post-market Study of its NPseal™
“The first cases demonstrate fast application and easy activation of the NPsealTM” stated Machiel van der Leest, CEO of Guard Medical. “This ease of use combined with its cost effectiveness makes prophylactic use of NPWT for closed surgical wounds possible.”
June 7, 2021
